Masimo (NASDAQ:MASI) Releases FY 2024 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.100-4.100 for the period, compared to the consensus estimate of 4.030. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.1 billion. Masimo also updated its FY 2025 guidance to 4.900-5.100 EPS.

Masimo Price Performance

MASI stock opened at $172.29 on Friday. The firm’s 50-day moving average price is $169.23 and its two-hundred day moving average price is $140.13. The stock has a market capitalization of $9.22 billion, a price-to-earnings ratio of 118.82 and a beta of 1.01. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a 12-month low of $101.61 and a 12-month high of $180.97.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. During the same quarter in the previous year, the firm posted $0.63 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, equities analysts predict that Masimo will post 4.03 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on MASI. Raymond James lifted their target price on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler increased their target price on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. BTIG Research lifted their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Masimo has a consensus rating of “Moderate Buy” and a consensus price target of $179.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.